Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERVFree Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on shares of Minerva Neurosciences from $11.00 to $7.00 and set a neutral rating on the stock in a research note on Thursday, May 2nd.

Get Our Latest Stock Analysis on NERV

Minerva Neurosciences Trading Down 1.9 %

Shares of NASDAQ:NERV opened at $2.52 on Friday. The stock has a fifty day simple moving average of $2.54 and a two-hundred day simple moving average of $5.14. Minerva Neurosciences has a 12-month low of $2.29 and a 12-month high of $13.49.

Minerva Neurosciences (NASDAQ:NERVGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.07. Research analysts predict that Minerva Neurosciences will post -1.89 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

(Get Free Report)

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.

See Also

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.